Ex-Commissioners See Mostly Positives In Public View Of US FDA After COVID

Three of the US FDA’s former leaders believe the agency is coming through COVID with its reputation intact. They still support making the agency independent of the broader Health & Human Services Department, but the urgency may be gone.

FDA's future's so bright. Photo illustration/Alamy, Shutterstock images
How bright will FDA's future be? • Source: photo illustration/Alamy, Shutterstock images

The US Food & Drug Administration’s somewhat tumultuous time in the spotlight of the COVID-19 response effort likely means a broader public appreciation for the “immense complexity” of the agency’s responsibilities, former Commissioner Andy von Eschenbach suggested during the Food & Drug Law Institute annual meeting on 18 May.

“I think the public has a much better appreciation of the challenges that the agency has to respond to,” von...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership